PDCD1 and melanoma: Loss-of-function mutations in IFNγ receptor signaling pathway genes JAK1 and JAK2 have been seen in melanoma patients who developed late relapses after initial successful anti-PD-1 therapy (144), as well as patients with primary resistance to this immunotherapy (145).